The Asia Pacific Lupus Collaboration (APLC) is a collaboration of expert lupus clinicians and researchers (the Investigators) from the Asia Pacific region, who have come together to improve outcomes for patients with systemic lupus erythematosus (SLE).
SLE, or lupus, is a chronic autoimmune disease that causes the body's immune system to attack many vital organs, resulting in a wide range of clinical features. SLE predominantly affects women and it is common among those of Asian ethnicity. There is no single effective targeted therapy for SLE. This means that, along with suffering symptoms of the disease, patients also suffer severe toxicity from the use of corticosteroids and broad-spectrum immunosuppressive therapies. Despite combination therapy with current drugs, many studies show that the majority of patients suffer inadequate disease control and are at risk of permanent organ damage over time.
The Asia Pacific region has a high frequency of SLE with high disease activity, which allows this region a special advantage in the ability to study lupus in depth. The APLC is taking this opportunity for collaborative research, and making contributions to knowledge on the disease, its treatment and treatment targets, on a global scale.
The APLC has >50 Investigators from 25 sites across 13 countries in the Asia Pacific region.